Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes
- 28 October 2020
- journal article
- editorial
- Published by Elsevier BV in Diabetes & Metabolism
- Vol. 47 (2), 101204
- https://doi.org/10.1016/j.diabet.2020.10.002
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up studyThe Lancet Diabetes & Endocrinology, 2019
- Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variablesThe Lancet Diabetes & Endocrinology, 2018
- Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and futureThe Lancet, 2013
- Adaptive immunity in obesity and insulin resistanceNature Reviews Endocrinology, 2012
- Why blockade of the renin–angiotensin system reduces the incidence of new-onset diabetesJournal of Hypertension, 2005
- Renin-angiotensin system inhibition prevents type 2 diabetes mellitus: Part 2. Overview of physiological and biochemical mechanismsDiabetes & Metabolism, 2004
- The Genetic Association DatabaseNature Genetics, 2004
- Improved Islet Morphology after Blockade of the Renin- Angiotensin System in the ZDF RatDiabetes, 2004
- Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin ResistanceScience, 1993